Rationale: Clonal hematopoiesis has been associated with increased mortality and cardiovascular disease. This condition can arise from somatic mutations in preleukemic driver genes within hematopoietic stem/progenitor cells. Approximately 40 candidate driver genes have been identified, but mutations in only 1 of these genes, TET2 (ten-eleven translocation-2), has been shown to casually contribute to cardiovascular disease in murine models.
S omatic DNA mutations accumulate over time in many tissues, and this is a hallmark of the aging process. 1 In particular, somatic mutations in preleukemic driver genes within hematopoietic stem/progenitor cell (HSPC) can confer fitness advantages leading to their clonal amplification. This process is referred to as clonal hematopoiesis. 2 This condition is prevalent in the elderly population, and it has been termed clonal hematopoiesis of indeterminate potential 3 or age-related clonal hematopoiesis. 4 Several recent studies have associated advanced clonal hematopoiesis with increased mortality [4] [5] [6] and with increased frequencies of cardiovascular disease (CVD) and stroke. 4, 7 Recently, we provided causal evidence for a link between somatic mutations in TET2 (ten-eleven translocation-2) and CVD in models of murine atherosclerosis and heart failure and provided details about its mechanism. 8, 9 TET2 is 1 of ≈40 candidate driver genes that have been associated with clonal hematopoiesis. 10 To date, there is an absence of information about the roles of driver genes, other than Tet2, in chronic disease. Thus, the development of procedures to facilitate the analysis of additional candidate driver genes is warranted.
Methods
The data, analytical methods, and study materials will be/have been made available to other researchers for the purposes of reproducing the results or replicating the procedures. The authors declare that all supporting data are available within the article and its Online Data Supplement. An expanded Methods section is available in the Online Data Supplement and includes detailed information on standard methods involving plasmids, lentivirus production, validation of guide RNA, isolation of lineage-negative cells and lentivirus transduction, mice, bone marrow transplantation, flow cytometry, Ang II (angiotensin-II) infusion, echocardiography, histology, quantitative polymerase chain reaction analysis, and statistics.
Results

CRISPR/Cas9-Mediated Tet2 Gene Disruption Promotes Hematopoietic Cell Expansion
To evaluate the efficiency of the lentivirus system to mutate driver genes in HSPCs, lineage-negative cells were isolated from wild-type mice and transduced ex vivo with a lentivirus vector encoding Cas9 (clustered regularly interspaced short palindromic repeat-associated 9)-GFP (green fluorescent protein) and transplanted into lethally irradiated wild-type mice ( Figure 1A Figure 1B ). Guide RNA candidates targeting Tet2 were selected after evaluation in NIH/3T3 by the T7 endonuclease I mismatch cleavage assay (Online Figure I) . To assess whether ex vivo Tet2 gene-edited HSPCs replicate the expansion characteristics of bone marrow cells from Tet2-knockout (KO) mice, the fractions of GFP-positive cells in the different peripheral blood cell lineages were determined at the 4-and 16-week time points ( Figure 1C ). This analysis revealed expansion characteristics that were similar to what was observed in our prior studies with Tet2-KO mice. 8, 9 To determine the degree of Tet2 editing by the lentivirus vector, DNA sequencing of the Tet2 locus was performed on DNA-isolated GFP-positive white blood cells. All the sequence reads revealed out-of-frame indel (insertion and deletion) mutations (3n+1, 3n+2) within exon 3 ( Figure 1D ), which are predicted to lead to a loss of gene function.
Phenotypes of Tet2 Gene Disruption in the Ang II Infusion Model
Having demonstrated the efficiency of the lentivirus delivery system on HSPC expansion, we next sought to examine whether Tet2 gene editing in HSPCs promotes pathological cardiac remodeling. The Ang II infusion model was chosen because it does not involve a major surgical manipulation. To validate this new model for studies of clonal hematopoiesis, Ang II was infused to mice that had undergone a competitive bone marrow transplantation using 10% conventional CD45.2 + Tet2-KO mice and 90% CD45.1 + wild-type mice (Online Figure  II) , as in our prior studies. 8, 9 Flow cytometry analysis of the different blood cell lineages, according to the gating strategy shown in Online Figure III , revealed the selective expansion of the Tet2-KO hematopoietic cells (Online Figure IV) 
Novelty and Significance
What Is Known?
• Clonal hematopoiesis may represent a new causal risk factor for cardiovascular disease.
• Clonal hematopoiesis can result from somatic mutations in any of the several preleukemic driver genes within hematopoietic stem cells.
• To date, the only driver gene evaluated for its impact on cardiovascular disease in an experimental setting is Tet2 (ten-eleven translocation-2).
What New Information Does This Article Contribute?
• Using lentivirus/CRISPR (clustered regularly interspaced short palindromic repeats) methodology, a system is developed that allows for the rapid introduction of mutations into driver genes of hematopoietic stem cells in mice.
• This system was used to show that inactivating mutations in Tet2 or Dnmt3a (DNA [cytosine-5]-methyltransferase 3a) within hematopoietic stem cells can promote experimental heart failure.
• Inactivating mutations in Tet2 and Dnmt3a differed in their ability to promote hematopoietic cell expansion in vivo and in patterns of inflammatory gene expression in macrophages in vitro, suggesting gene-specific actions.
DNMT3A is recognized to be the most prevalent clonal hematopoiesis driver gene in the elderly population, conservatively estimated to affect millions of individuals in the United States alone.
Here, it is shown that an inactivating mutation in Dnmt3a will promote pathological remodeling in experimental heart failure. These studies suggest multiple driver genes, beyond Tet2, can impact cardiovascular disease and that gene-specific effects will be observed. These data provide further support to hypothesis that there is a common mechanistic basis between age-associated cardiovascular disease and hematologic cancer.
compared with mice transplanted with 100% wild-type cells that were comprised of 10% CD45.2 + cells (Figure 2A ). At the termination of the experiment, hearts in mice receiving 10% Tet2-KO bone marrow displayed an increase in cardiac weight ( Figure 2B ), an increase in cardiac myocyte cross sectional area ( Figure 2C ), and an increase in interstitial fibrosis ( Figure 2D ; Online Figure V ). Finally, a similar cardiac phenotype could also be detected in myeloid-specific, Tet2-deficient mice that were infused with Ang II (Online Figure VI) , consistent with observations in other models of myocardial dysfunction. 9 The next series of Ang II-infusion experiments involved mice transplanted with HSPC that underwent Tet2 editing using the lentivirus/CRISPR (clustered regularly interspaced short palindromic repeats) system (Online Figure II) . Similar to mice subjected to the conventional, competitive bone marrow transplantation with Tet2-KO cells, mice transplanted with CRISPR-edited HSPC displayed greater reductions in cardiac function as determined by echocardiography ( Figure 2E ). These mice also displayed an increase in cardiac mass, cardiac 
CRISPR/Cas9-Mediated Hematopoietic Dnmt3a Gene Disruption Promotes Cardiac Dysfunction
Having demonstrated that the lentivirus/CRISPR/Ang II system can be used to analyze the role of clonal hematopoiesis in CVD processes, mice with Dnmt3a (DNA [cytosine-5]-methyltransferase 3a)-edited HSPC were evaluated in the Ang II model. The validation of guide RNA targeting Dnmt3a was performed using the T7 endonuclease I mismatch cleavage assay and immunoblotting (Online Figure ID and IE) . Consistent with previous reports, [11] [12] [13] Dnmt3a-disrupted HSPCs did not undergo selective expansion during the 4-month time course of these experiments ( Figure 3A) . Thus, a relatively low level of chimerism, similar to that of nonedited cells, was observed in the peripheral blood populations. To determine the status of Dnmt3a editing by the lentivirus vector, sequencing of the Dnmt3a locus was performed on DNA isolated from GFP-positive white blood cells. All sequence reads revealed out-of-frame mutations (3n+1, 3n+2), which lead to premature stop codons in exon 17 of Dnmt3a gene ( Figure 3B ) and a loss of enzymatic activity. 14 Mice transplanted with Dnmt3a-edited HSPC showed a reduction in cardiac function by echocardiographic analysis and an increase in cardiac mass 8 weeks after systemic Ang II administration ( Figure 3C and 3D) . Mice receiving Dnmt3a-edited HSPC also displayed greater cardiac fibrosis and greater cardiac myocyte cross-sectional area in tissue sections (Figure 3E and 3F; Online Figure VC) . The Dnmt3a-edited HSPC condition led to greater renal fibrosis (Online Figure VIIC) .
Dnmt3a Disruption Enhances Inflammation
The recruitment and activation of peripheral myeloid cells contributes to cardiac dysfunction in the Ang II infusion model. 15, 16 To address the role of Dnmt3a gene disruption in myeloid cells, we established Dnmt3a-deficient J774.1 myeloid cell line using the lentivirus/CRISPR system. After sorting and amplification, GFP-positive cells displayed a marked reduction in Dnmt3a protein expression by immunoblotting ( Figure 4A ). Using the same system, Tet2 deficiency was also established in J774.1 cells for comparative analyses. Consistent with our previous results, Tet2 disruption led to increased inflammatory chemokine/cytokine transcript expression after lipopolysaccharide stimulation. 8, 9 Dnmt3a deficiency in J774.1 cells also displayed greater inflammatory responses after lipopolysaccharide stimulation ( Figure 4B) . However, the patterns of inflammatory mediator induction in the Dnmt3a-and Tet2-deficient states differed. Whereas IL (interleukin)-6 and Ccl5 were similarly induced in both conditions, IL-1β was significantly upregulated in Tet2-edited cells, but there was only a trend in Dnmt3a-edited cells. Conversely, Cxcl1 (CXC chemokine ligand) and Cxcl2 were upregulated only in Dnmt3a-deficient cells compared with the control condition.
Consistent with observations of greater inflammatory responses in the Dnmt3a-deficient state, greater macrophage accumulation was observed in the myocardium after Ang II infusion ( Figure 4C ). This was accompanied by elevated levels Statistical analysis was evaluated by Mann-Whitney U test. G, Representative images and analysis of WGA staining of the heart sections from hearts of Tet2 (ten-eleven translocation-2)-indel (insertion and deletion) mice and control mice at the end of the study (scale bar=1 mm). Statistical analysis was evaluated by 2-tailed unpaired Student t test. H, Representative images and analysis of Picrosirius staining of the heart sections from hearts of Tet2-indel mice and control mice at the end of the study (scale bar=25 μm). Statistical analysis was evaluated by 2-tailed unpaired Student t test. In E-H, n=6 per group were analyzed. **P<0.01, ***P<0.001, ****P<0.0001. CSA indicates cross-sectional area; FS, fractional shortening; HW, heart weight; and TL, tibia length.
of transcripts of immune cell markers, including CD68, CD3e, CD4, and CD8, suggesting that hematopoietic Dnmt3a deficiency leads to an increase in myocardial inflammation ( Figure 4D ).
Discussion
Studies have associated the clonal expansion of HSPC with mortality and increased CVD risk. 4, 5, 7 Clonal hematopoiesis can be caused by somatic mutations in ≥40 candidate driver genes, and it is likely that these different drivers will confer gene-specific effects on pathological processes. To date, studies focused on Tet2, which functions to promote a DNA hydroxymethylation and to recruit histone deacetylases to gene regulatory sequences, 2 have provided the only evidence that these somatic mutations can causally contribute to CVD. Given the challenge of evaluating many other driver genes, we have developed procedures to facilitate the analysis of clonal hematopoiesis in CVD. The described system uses lentiviral vectors to transduce HSPC and CRISPR methodology to create indel mutations in candidate driver gene. Although off-target mutations are a potential concern, this system allows the ex vivo manipulation of HSPC that can then be implanted into wild-type mice and thereby provide a more versatile and rapid approach to assess HSPC clonal expansion and its systemic consequences than the conventional murine transgenic/knockout technology. Similar techniques have been used to edit driver genes in a model of myeloid malignancy. 17 To evaluate CVD, gene-edited mice were infused with Ang II-a peptide hormone involved in the pathologies of vascular, renal, and cardiac diseases. 18 Under these conditions, CRISPRmediated indels in Tet2 of HSPC led to the expansion of mutant cells and worsened cardiac remodeling, serving to validate the system and extend our prior findings. 8, 9 We then applied this technology to evaluate the consequences of inactivating mutations in Dnmt3a. Mutations in DNMT3A represent the most prevalent driver gene associated with clonal hematopoiesis in the elderly population, [4] [5] [6] and it can conservatively be estimated that millions of Americans are afflicted with DNMT3A-related clonal hematopoiesis. This protein is a de novo DNA methyltransferase, and it is expressed in long-term HSPC. 19 Here, we show that lentivirus/ CRISPR-mediated disruption of hematopoietic Dnmt3a results in greater cardiac hypertrophy, diminished ejection fraction, and increased fibrosis after Ang II administration. Cardiac tests. E, Representative images and analysis of Picrosirius staining of the heart sections from hearts of Dnmt3a-indel mice and control mice at the end of the study (scale bar=1 mm). Statistical analysis was evaluated by 2-way ANOVA with Tukey multiple comparison tests. F, Representative images and analysis of WGA (wheat germ agglutinin) staining of the heart sections from hearts of Dnmt3a-indel mice and control mice at the end of the study (scale bar=25 μm). Statistical analysis was evaluated by 2-way ANOVA with Tukey multiple comparison tests. In D-F, n=10 for Ang II groups and n=7 for PBS groups were analyzed. NS indicates nonsignificant. ***P<0.001, ****P<0.0001. CSA indicates cross-sectional area; FS, fractional shortening; Mono, monocyte; Neut, neutrophil; TL, tibia length; and WBC, white blood cell. July 20, 2018 dysfunction was associated with greater macrophage accumulation and the elevated expression of immune cell markers in the myocardium. Consistent with previous studies on Tet2, 8, 9 these effects tended to be observed late in the course of the pathological process, suggesting that clonal hematopoiesis impairs the resolution of inflammation. In cell culture studies, the inactivation of either Dnmt3a or Tet2 led to increased cytokine expression, but the effects differed qualitatively and quantitatively suggesting that they confer gene-specific effects resulting from mechanistic differences between these 2 proteins.
Inactivating mutations in Dnmt3a and Tet2 led to markedly different HSPC expansion characteristics. The robust expansion of Tet2-deficient cells into multiple blood cell lineages was observed after the implantation of CRISPR-edited HSPC, and these results are consistent with observations from experiments that using a competitive transplantation approach using a 1:9 ratio of Tet2-KO:wild-type bone marrow 8, 9 ( Figure 1B ; Online Figure II ). In contrast, there was no detectable expansion of Dnmt3a-deficient peripheral blood cells over the time course of our study. This finding is consistent with previous reports showing that Dnmt3a-null HSPCs are observed to expand in aged mice or only after sequential bone marrow transplantations. 12, 13, 20 Although Dnmt3a and Tet2 appeared to similarly affect cardiac pathology in the Ang II model, the lack of Dnmt3a-deficient hematopoietic cell expansion suggests that Dnmt3a may be more potent than Tet2 in promoting CVD.
Dnmt3a has been demonstrated to have multiple roles in the regulation of inflammation. Cao et al reported that Dnmt3a controls inflammation in peritoneal macrophage by acting on HDAC9 to cause TBK1 (TANK-binding kinase 1) deacetylation. It is also reported that Dnmt3a controls inflammatory cytokine expression by regulating the expression of the scaffold protein IQGAP2 (IQ motif containing GTPase activating protein 2) in mast cell, 21 and the expression of DNMT3A is associated with the methylation status and the activity of IL-6 gene in synovial fibroblasts from patients with osteoarthritis. 22 In the current study, we show that Dnmt3a deficiency can alter the function of myeloid cells and promote the inflammation via the upregulation of specific cytokines and chemokines. These findings suggest that Dnmt3a-mediated clonal hematopoiesis could be causally associated with CVDs by promoting prolonged inflammatory responses in myeloid cells. However, we do not rule out the possibility that other blood cells could also contribute to the pathogenesis of CVD associated with the loss of Dnmt3a (on Tet2) in hematopoietic cells. 
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